An antibody raised against Notch1, a transmembrane receptor involved in the Notch signalling pathway with links to numerous cancers.
Catalogue number crb2005746 Antibody Anti-Notch1 antibody Antigen Peptide KLH conjugated synthetic peptide crb1200955 Protein ID UniProtKB - P46531 (Human), Q07008 (Rat), Q01705 (Mouse) Aliases Neurogenic locus notch homolog protein 1, Translocation-associated notch protein TAN-1, Notch 1, hN1, Notch Receptor 1, Notch 1, TAN1, Translocation-Associated Notch Protein TAN-1, Neurogenic Locus Notch Homolog Protein, HN1 Cross-Reactivity Human, Rat, Mouse Host Species Rabbit Antibody Type Polyclonal Concentration 2.0 mg/ml Glycine Target Notch1 Family NOTCH family Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/thaw cycles. References
Gharaibeh et al., (2020). Notch1 in cancer therapy: possible clinical implications and challenges. Mol. Pharmacol., 98(5): 559. doi: 10.1124/molpharm.120.000006.
Miao et al., (2020). NOTCH1 activation compensates for BRCA1 deficiency and promotes triple-negative breast cancer formation. Nat. Commun., 11(1): 3256. doi: 10.1038/s41467-020-16936-9.
Notch1 is part of the Notch family, receptors involved in the Notch signalling pathway. Notch1 has the characteristic N-terminal EGF-like repeats and C-terminal LNR domains. Notch1 forms a complex with ligands to prevent signalling.
The Notch signalling pathway is involved in cell fate specification, differentiation, proliferation, and survival processes. Activation of Notch1 is correlated with mammary tumorigenesis in mice. Increased expression of Notch receptors is linked to several cancer types, including cervical, colon, head and neck, lung, renal, pancreatic, leukaemia, and breast cancer. Mutations directly affect survival rates in acute myeloid leukaemia. Notch inhibitors aim to downregulate the Notch signalling pathway. γ-secretase inhibitors block all Notch receptors, Notch1 short interference RNA, or Notch1 monoclonal antibodies specifically target Notch1. Notch1 inhibitors are a target to downregulate Notch signalling in breast cancer chemotherapy.
Diseases associated with Notch1 are aortic valve disease 1 and Adams-Oliver syndrome 5.